Breakout Ventures

Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Twelve is a carbon transformation company converting captured carbon dioxide into valuable chemicals, fuels, and other essential products. Their technology eliminates emissions by turning CO2 into essential products that are made from fossil fuels. They specialize in the fields of CO2 electrocatalysis and electrochemical reactor design.

Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.

Phantom Neuro develops innovative muscle-machine interfaces that enhance robotic limb rehabilitation. The company focuses on creating solutions that improve mobility for users by integrating neurotechnology with robotic systems. Through its minimally invasive approach, Phantom Neuro aims to facilitate precise control of robotic limbs, allowing for more natural movement and better user experiences. The company is committed to advancing the field of neurotechnology, providing valuable tools for rehabilitation and improving the quality of life for individuals with mobility challenges. Phantom Neuro also explores various applications of its technologies, contributing to the broader field of assistive robotics.

Circuit Clinical was born from the experiences of a physician conducting clinical research in his busy private practice. From the core belief that patients prefer to learn about clinical research from healthcare providers they trust, came the vision for Circuit Clinical. Since 2015 we've built one of the largest Integrated Research Organizations [IRO] in the US. Our focus on physician and participant engagement gives us a distinct advantage with the identification of motivated participants through direct HIPAA/FDA-compliant Electronic Medical Record (EMR) review. Coupled with our technology products that enhance the participant and physician experience, Circuit Clinical provides our network of more than 1 million patients, our physicians, and our sponsor partners with a new path forward in clinical research.

Zymochem provides a carbon-efficient bio-manufacturing platform that converts renewable feedstocks into bio-based materials without compromising price, performance, scale, or sustainability while minimizing CO2 loss during production. It also accelerates a real-zero economy by relieving carbon emissions in product development, use, and end-of-life.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Twelve is a carbon transformation company converting captured carbon dioxide into valuable chemicals, fuels, and other essential products. Their technology eliminates emissions by turning CO2 into essential products that are made from fossil fuels. They specialize in the fields of CO2 electrocatalysis and electrochemical reactor design.

Circuit Clinical was born from the experiences of a physician conducting clinical research in his busy private practice. From the core belief that patients prefer to learn about clinical research from healthcare providers they trust, came the vision for Circuit Clinical. Since 2015 we've built one of the largest Integrated Research Organizations [IRO] in the US. Our focus on physician and participant engagement gives us a distinct advantage with the identification of motivated participants through direct HIPAA/FDA-compliant Electronic Medical Record (EMR) review. Coupled with our technology products that enhance the participant and physician experience, Circuit Clinical provides our network of more than 1 million patients, our physicians, and our sponsor partners with a new path forward in clinical research.

CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases, revolutionizing diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California.

Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft. The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. It was founded in 2009 and is headquartered in Seattle, Washington.

Checkerspot is a materials innovation company that designs materials at a molecular level. The company is driven by a mission to use the power of biotechnology to expand the palette of molecular building blocks for high-performance and sustainable materials.

ShiraTronics develops neuromodulation technology to combat debilitating chronic migraine. The company is driven by a mission to transform the lives of those living with chronic migraine.

CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases, revolutionizing diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California.

Curie Co is a life science company that engineers enzymes and marine biomaterials to replace harmful and banned chemicals. The company's mission is to replace chemicals banned by the FDA with 100% sustainable and safe ingredients from recycled marine biomaterials (branded OceanSafe) for use in 100s of products you can find on the shelves of Walmart, Target and CVS—all without inflating their price points. To this end, consumers can get their same favorite products, at the same price point, without doing harm to the environment or themselves—and Curie Co is positioned to become a trusted supplier and world leader of engineered enzymes and biopolymers.

Checkerspot is a materials innovation company that designs materials at a molecular level. The company is driven by a mission to use the power of biotechnology to expand the palette of molecular building blocks for high-performance and sustainable materials.

Phylagen, Inc. is a data analytics company leveraging artificial intelligence to harness the vast, unseen world of microbes. Phylagen uses DNA sequencing and machine learning to turn the largest untapped dataset on the planet, the environmental microbiome, into insights for customers across numerous industries.

Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft. The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. It was founded in 2009 and is headquartered in Seattle, Washington.

CytoVale is a medical technology company that focuses on advancing early detection technologies to diagnose immune-mediated diseases, revolutionizing diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California.

Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft. The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. It was founded in 2009 and is headquartered in Seattle, Washington.

3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.

Modern Meadow is a purpose-driven company positioned at the intersection of material science and biology with a mission to be a catalyst for real-world impact on people and the planet. Modern Meadow’s proprietary Bio-Alloy and Bio-Farm technology application platforms harness the unique properties of tuned proteins to sustainably move the world away from petrochemical and animal-derived inputs without compromising on performance. These innovations can drop into any existing infrastructures for immediate scalable adoption in the materials, beauty, and other industries. Modern Meadow's close relationship with development partners and production facilities allows companies partnering with Modern Meadow to feel confident knowing our products are 100% traceable from Lab-to-Brand.